Trade Mark Journal No.2026/034 21 August 2026

UK00004425833 4 August 2026 (5)

JIBRELSO

International priority date claimed: 6 February 2026 (United States of America) (99639512)

Class 5: Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, autoimmune diseases, solid organ transplant rejection, autoinflammatory diseases, blood diseases, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, Alzheimer’s disease, autism spectrum disorder, and musculoskeletal and skin diseases; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes.

Bristol-Myers Squibb Company

Representative: Sipara Limited